Article Sidebar
Published:
Jun 5, 2023DOI:
10.4314/tjpr.v22i5.4Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
COLEC12 expression participates in trophoblast insulin resistance, and reverses celecoxib-mediated inhibition of COX2-PGE2 axis in gestational diabetes
Abstract
Purpose: To evaluate the contribution of collectin subfamily member 12 (COLEC12) in insulin resistance associated with gestational diabetes mellitus (GDM).
Methods: Insulin resistance was induced in human placental trophoblast (HTR-8/SVneo) cells in vitro by incubating them with 1 μM insulin for 48 h. Expression of COLEC12 was assessed using western blot and quantitative real time-polymerase chain reaction (qRT-PCR). Distribution of glucose transporters GLUT1 and GLUT4 was visualized using immunofluorescent staining. Furthermore, the level of reactive oxygen species (ROS) was evaluated by flow cytometry.
Results: Insulin-resistant HTR-8/SVneo (IR-HTR-8/SVneo) cells showed significantly elevated COLEC12 expression (p < 0.001). Knocking down of COLEC12 in these cells led to a significant reduction in GLUT1 expression, and increase in both glucose consumption and GLUT4 expression (p < 0.001). Furthermore, COLEC12 knockdown levels of ROS increased SOD expression in IR-HTR8/SVneo, while knockdown of COLEC12 reduced p-insulin receptor substrate (IRS) (Ser307) protein expression, but increased p-IRS-1 (Tyr896), p-insulin receptor β (IRβ) (Tyr1361), and p-AKT levels. COLEC12 knockdown also decreased cyclooxygenase-2 (COX-2) expression, resulting in lower prostaglandin E2 (PGE2) levels in IR-HTR-8/SVneo. COLEC12 over-expression attenuated celecoxibinduced increase in glucose consumption, resulting in decreased COX2 and PGE2 levels.
Conclusion: COLEC12 in IR-HTR-8/SVneo cells has antioxidant effects that protect against insulin resistance. This protective effect is achieved through the down-regulation of COX-2/PGE2. These findings provide a potential strategy for the treatment of GDM.
